Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

40.19
-3.0000-6.95%
Post-market: 40.190.00000.00%16:05 EDT
Volume:1.69M
Turnover:68.57M
Market Cap:4.76B
PE:-7.63
High:42.55
Open:42.33
Low:39.81
Close:43.19
Loading ...

Optimistic Buy Rating for Cytokinetics Driven by Aficamten’s Market Potential and Undervalued Shares

TIPRANKS
·
07 Feb

JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
07 Feb

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
07 Feb

Camzyos news has negative readthroughs for Cytokinetics, says BofA

TIPRANKS
·
07 Feb

Positive Outlook for Cytokinetics Amid Rising HCM Market Demand and Developments

TIPRANKS
·
07 Feb

Cytokinetics’ Aficamten Poised for Market Success Amid Competitive Dynamics and Expanding HCM Opportunities

TIPRANKS
·
06 Feb

Cytokinetics share weakness on updated Camzyos REMS overdone, says Truist

TIPRANKS
·
06 Feb

B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating

MT Newswires Live
·
05 Feb

Cytokinetics’ Aficamten: Promising Phase III Trials and Market Expansion Justify Buy Rating

TIPRANKS
·
05 Feb

Top Exec Makes Notable Move with Cytokinetics Stock!

TIPRANKS
·
05 Feb

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

THOMSON REUTERS
·
30 Jan

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Zacks
·
30 Jan

What Are Analysts Talking About Cytokinetics (CYTK)?

Insider Monkey
·
28 Jan

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Zacks
·
24 Jan

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga
·
23 Jan